BioVie Inc. (NASDAQ:BIVI) Short Interest Update

BioVie Inc. (NASDAQ:BIVI) saw a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 2,090,000 shares, a growth of 13.6% from the November 30th total of 1,840,000 shares. Based on an average trading volume of 5,990,000 shares, the short-interest ratio is currently 0.3 days.

BioVie Stock Performance

NASDAQ BIVI traded down $0.09 during trading hours on Tuesday, hitting $2.00. 1,200,976 shares of the company’s stock were exchanged, compared to its average volume of 1,662,129. The business’s 50 day moving average is $2.71 and its 200-day moving average is $1.96. BioVie has a 12-month low of $1.04 and a 12-month high of $33.10. The firm has a market capitalization of $35.54 million, a P/E ratio of -0.17 and a beta of 0.40.

BioVie (NASDAQ:BIVI) last announced its quarterly earnings data on Monday, September 30th. The company reported ($6.60) earnings per share for the quarter.

About BioVie

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.